182 related articles for article (PubMed ID: 23716000)
21. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
Hsu FT; Liu YC; Chiang IT; Liu RS; Wang HE; Lin WJ; Hwang JJ
Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012
[TBL] [Abstract][Full Text] [Related]
22. CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer.
Devapatla B; Sharma A; Woo S
PLoS One; 2015; 10(9):e0139237. PubMed ID: 26414070
[TBL] [Abstract][Full Text] [Related]
23. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA-195 suppresses angiogenesis and metastasis of hepatocellular carcinoma by inhibiting the expression of VEGF, VAV2, and CDC42.
Wang R; Zhao N; Li S; Fang JH; Chen MX; Yang J; Jia WH; Yuan Y; Zhuang SM
Hepatology; 2013 Aug; 58(2):642-53. PubMed ID: 23468064
[TBL] [Abstract][Full Text] [Related]
25. Acquired Resistance with Epigenetic Alterations Under Long-Term Antiangiogenic Therapy for Hepatocellular Carcinoma.
Ohata Y; Shimada S; Akiyama Y; Mogushi K; Nakao K; Matsumura S; Aihara A; Mitsunori Y; Ban D; Ochiai T; Kudo A; Arii S; Tanabe M; Tanaka S
Mol Cancer Ther; 2017 Jun; 16(6):1155-1165. PubMed ID: 28246302
[TBL] [Abstract][Full Text] [Related]
26. CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer.
Gao DY; Lin TsT; Sung YC; Liu YC; Chiang WH; Chang CC; Liu JY; Chen Y
Biomaterials; 2015 Oct; 67():194-203. PubMed ID: 26218745
[TBL] [Abstract][Full Text] [Related]
27. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
Huang D; Ding Y; Li Y; Luo WM; Zhang ZF; Snider J; Vandenbeldt K; Qian CN; Teh BT
Cancer Res; 2010 Feb; 70(3):1053-62. PubMed ID: 20103629
[TBL] [Abstract][Full Text] [Related]
28. Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma.
Kuczynski EA; Kerbel RS
Chin J Cancer; 2016 Nov; 35(1):97. PubMed ID: 27887628
[TBL] [Abstract][Full Text] [Related]
29. Polycomb chromobox 4 enhances migration and pulmonary metastasis of hepatocellular carcinoma cell line MHCC97L.
Mei Z; Jiao H; Wang W; Li J; Chen G; Xu Y
Sci China Life Sci; 2014 Jun; 57(6):610-7. PubMed ID: 24838576
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3.
Li WC; Ye SL; Sun RX; Liu YK; Tang ZY; Kim Y; Karras JG; Zhang H
Clin Cancer Res; 2006 Dec; 12(23):7140-8. PubMed ID: 17145839
[TBL] [Abstract][Full Text] [Related]
31. Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells.
Sprinzl MF; Reisinger F; Puschnik A; Ringelhan M; Ackermann K; Hartmann D; Schiemann M; Weinmann A; Galle PR; Schuchmann M; Friess H; Otto G; Heikenwalder M; Protzer U
Hepatology; 2013 Jun; 57(6):2358-68. PubMed ID: 23424039
[TBL] [Abstract][Full Text] [Related]
32. Hepatic androgen receptor suppresses hepatocellular carcinoma metastasis through modulation of cell migration and anoikis.
Ma WL; Hsu CL; Yeh CC; Wu MH; Huang CK; Jeng LB; Hung YC; Lin TY; Yeh S; Chang C
Hepatology; 2012 Jul; 56(1):176-85. PubMed ID: 22318717
[TBL] [Abstract][Full Text] [Related]
33. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
34. Sorafenib enhances proteasome inhibitor-mediated cytotoxicity via inhibition of unfolded protein response and keratin phosphorylation.
Honma Y; Harada M
Exp Cell Res; 2013 Aug; 319(14):2166-78. PubMed ID: 23727131
[TBL] [Abstract][Full Text] [Related]
35. Convection-enhanced delivery of sorafenib and suppression of tumor progression in a murine model of brain melanoma through the inhibition of signal transducer and activator of transcription 3.
Zou Z; Yin Y; Lin J; Hsu LC; Brandon VL; Yang F; Jove R; Jandial R; Li G; Chen MY
J Neurosurg; 2016 May; 124(5):1310-8. PubMed ID: 26544779
[TBL] [Abstract][Full Text] [Related]
36. Use of Ultrasmall Superparamagnetic Iron Oxide Enhanced Susceptibility Weighted Imaging and Mean Vessel Density Imaging to Monitor Antiangiogenic Effects of Sorafenib on Experimental Hepatocellular Carcinoma.
Yang S; Lin J; Lu F; Han Z; Fu C; Gu H
Contrast Media Mol Imaging; 2017; 2017():9265098. PubMed ID: 29097941
[TBL] [Abstract][Full Text] [Related]
37. Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment.
Horwitz E; Stein I; Andreozzi M; Nemeth J; Shoham A; Pappo O; Schweitzer N; Tornillo L; Kanarek N; Quagliata L; Zreik F; Porat RM; Finkelstein R; Reuter H; Koschny R; Ganten T; Mogler C; Shibolet O; Hess J; Breuhahn K; Grunewald M; Schirmacher P; Vogel A; Terracciano L; Angel P; Ben-Neriah Y; Pikarsky E
Cancer Discov; 2014 Jun; 4(6):730-43. PubMed ID: 24687604
[TBL] [Abstract][Full Text] [Related]
38. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.
Gridelli C; Maione P; Del Gaizo F; Colantuoni G; Guerriero C; Ferrara C; Nicolella D; Comunale D; De Vita A; Rossi A
Oncologist; 2007 Feb; 12(2):191-200. PubMed ID: 17296815
[TBL] [Abstract][Full Text] [Related]
39. Sorafenib inhibits macrophage-induced growth of hepatoma cells by interference with insulin-like growth factor-1 secretion.
Sprinzl MF; Puschnik A; Schlitter AM; Schad A; Ackermann K; Esposito I; Lang H; Galle PR; Weinmann A; Heikenwälder M; Protzer U
J Hepatol; 2015 Apr; 62(4):863-70. PubMed ID: 25463538
[TBL] [Abstract][Full Text] [Related]
40. An investigation of the effect of sorafenib on tumour growth and recurrence after liver cancer resection in nude mice independent of phosphorylated extracellular signal-regulated kinase levels.
Wang Z; Hu J; Qiu SJ; Huang XW; Dai Z; Tan CJ; Zhou J; Fan J
Expert Opin Investig Drugs; 2011 Aug; 20(8):1039-45. PubMed ID: 21671804
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
